“Our purpose is to translate cutting edge research andinnovation into measurable health gains for MSers inLondon, across the UK, and globally.”

Thank you

• Alison

• Jyoti

• David B / Gareth (MD1 & MD2)

• UCLP

• Barts-MS (QMUL, RLH, Basildon, Chelmsford, Southend)

• MS@UCL (UCL, UCLH)

• Royal Free (Watford, Chase Farm, L&D, Stevenage)

• Queens Romford

The past

Phenytoin Optic Neuritis Study

INSPIRE Study

UCLP clinical trials

The present

PROXIMUS Study

SMART Study

UCLP neuroprotection clinical trials

The future

Spasticity

ARTEMIS Study

ZEUS TRIAL

UCLP clinical trials

Vs.

Trial activity targeting progressive pathology

MRI Events

1st clinicalattack

Time (Years)

Subclinical disease

Inflammation

Brain volume loss

Neuroaxonal loss

Dis

ease

Sev

erit

y

SPMSRRMS

1st MRI lesion

Relapses

CISRIS R-SPMS

RIS = radiologically isolated syndrome; CIS = clinically isolated syndrome, RRMS = relapsing-remitting MS; R-SPMS = relapsing secondary progressive MS; SPMS = secondary progressive MS; PPMS = primary progressive MS

SPMS: Natalizumab, Siponimod, DMF

Late SPMS: SMART STUDYfluoxetine, amiloride, riluzole

Early SPMS:oxcarbazepine

CIS: PHENYTOIN RRMS: ? DE-FLAMES STUDY

PPMS

PPMS: Fingolimod, Ocrelizumab, Laquinimod

SP&PPMS: Ibudilast

X

Treatment Update

DMT

1. Interferon-beta (Betaferon, Avonex, Rebif, Extavia)

2. Glatiramer Acetate (Copaxone)

3. Natalizumab (Tysabri)4. Fingolimod (Gilenya)

5. Teriflunomide (Aubagio)6. BG12 (Tecfidera)7. Alemtuzumab (Lemtrada)

8. Laquinimod9. Ocrelizumab10. Daclizumab11. Sopinimod

Symptomatic

1. THC/CBD (Sativex)

2. 4-aminopyridine (Fampridine)

3. VSN16 (Canbex)

• 10 minute talk• 10 Q&A• 10 minute table discussion

• 3 minute pitch from ‘MS Researcher’ at your table

• 7 minutes of Q’s• “MS Researcher” moves!

• 10 minute talk• 10 Q&A• 10 minute table discussion

• 3 minute pitch from ‘MS Researcher’ at your table

• 7 minutes of Q’s

#msresearchday

TrishnaStrictlyMouse

MouseDoctor